{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:37:28Z","timestamp":1776771448994,"version":"3.51.2"},"reference-count":18,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0009","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:39:24Z","timestamp":1776767964000},"source":"Crossref","is-referenced-by-count":0,"title":["Insulin prescribing in accordance with the guidelines for type II diabetes: An analysis of billing data of a German statutory health insurance carrier, the Allgemeine Ortskrankenkasse (AOK) Hessen"],"prefix":"10.3238","author":[{"given":"Bernardo","family":"Mertes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Zeise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybille","family":"G\u00f6dde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Kloos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Klinge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Til","family":"Uebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"10.3238\/arztebl.m2026.0009_ref1","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837\u201353. Erratum in: Lancet 1999; 354: 602","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"10.3238\/arztebl.m2026.0009_ref2","doi-asserted-by":"crossref","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005\u201312","DOI":"10.1001\/jama.281.21.2005"},{"key":"10.3238\/arztebl.m2026.0009_ref3","unstructured":"Robert Koch-Institut: Type 2 diabetes medication\u2014adults: Results of the Diabetes Surveillance 2015\u20132024. doi: 10.25646\/12342; p. 1\/6."},{"key":"10.3238\/arztebl.m2026.0009_ref4","unstructured":"Qualit\u00e4tsbericht 2023: Disease-Management-ProgrammeNord www.kvno.de\/fileadmin\/shared\/pdf\/print\/berichte\/dmp-berichte\/qualbe_dmp_23.pdf?v=1733742742 (last accessed on 26 November 2025)."},{"key":"10.3238\/arztebl.m2026.0009_ref5","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Nationale VersorgungsLeitlinie Typ-2-Diabetes \u2013 Langfassung. Version 4 2014. www.ddg.info\/fileadmin\/user_upload\/05_Behandlung\/01_Leitlinien\/Evidenzbasierte_Leitlinien\/dm-therapie-1aufl-vers4-lang.pdf (last accessed on 8 December 2025)"},{"key":"10.3238\/arztebl.m2026.0009_ref6","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Nationale VersorgungsLeitlinie Typ-2-Diabetes \u2013 Langfassung. Version 3.0. 2023. (last accessed 26 November 2025)."},{"key":"10.3238\/arztebl.m2026.0009_ref7","unstructured":"Deutsche Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin e.V.: DEGAM-Anwenderversion als Addendum zur Nationalen VersorgungsLeitlinie (NVL) Typ-2-Diabetes. 2025. www.degam.de\/files\/Inhalte\/Leitlinien-Inhalte\/Dokumente\/Beteiligungen%20Leitlinien\/NVL-001_Typ-2-Diabetes\/DEGAM%20Anwenderversion\/anwenderversion-2025\/degam-ll-diabetes-anwender-add-2025\u201317_11_2025.pdf (last accessed on 23 November 2025)"},{"key":"10.3238\/arztebl.m2026.0009_ref8","unstructured":"Gemeinsamer Bundesausschuss: Richtlinie des Gemeinsamen Bundesausschusses zur Zusammenf\u00fchrung der Anforderungen an strukturierte Behandlungsprogramme nach \u00a7 137f Absatz 2 SGB V (DMP-Anforderungen-Richtlinie\/DMP-A-RL). 2024 www.g-ba.de\/downloads\/62-492-3798\/DMP-A-RL_2024-04-18_iK-2024-10-01.pdf (last accessed on 17 July 2025)."},{"key":"10.3238\/arztebl.m2026.0009_ref9","unstructured":"Behandlungs- und Schulungsprogramm f\u00fcr bedarfsgerechte Insulintherapie bei Typ 2 Diabetes, Bundesamt f\u00fcr Soziale Sicherung, Disease Management Programme, Anhang 1 Schulungsprogramme f\u00fcr Patientinnen und Patienten, Seite 3, Stand: 10. November 2025 www.bundesamtsozialesicherung.de\/fileadmin\/redaktion\/DMP\/DMP1\/2025-11-10_Anhang_1_Patienten-Schulungsprogramme-DMP.pdf (last accessed on 26 November 2025)."},{"key":"10.3238\/arztebl.m2026.0009_ref10","doi-asserted-by":"crossref","unstructured":"Mertes B, G\u00f6dde S, Piorkowski M, Kramer G, M\u00fcller UA, Kuniss N: Successful treatment with bedtime basal insulin added to metformin without weight gain or hypoglycaemia over three years. J Clin Med 2020; 9: 1153","DOI":"10.3390\/jcm9041153"},{"key":"10.3238\/arztebl.m2026.0009_ref11","doi-asserted-by":"crossref","unstructured":"Gallwitz B, Aberle J, Birkenfeld AL, et al.: Praxisempfehlungen der Deutschen Diabetes Gesellschaft Therapie des Typ-2-Diabetes. Diabetologie und Stoffwechsel 2024; 19: S186\u2013S202","DOI":"10.1055\/a-2312-0315"},{"key":"10.3238\/arztebl.m2026.0009_ref12","doi-asserted-by":"crossref","unstructured":"Monami M, Marchionni N, Mannucci E: Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis. Diabet Res Clin Pract 2008; 81: 184\u20139","DOI":"10.1016\/j.diabres.2008.04.007"},{"key":"10.3238\/arztebl.m2026.0009_ref13","unstructured":"MEDIAS 2 BOT + SIT + CT (MEDIAS 2 BSC), Bundesamt f\u00fcr Soziale Sicherung, Disease Management Programm: Schulungsprogramme f\u00fcr Patientinnen und Patienten. Anhang. Stand: 10. November 2025 www.bundesamtsozialesicherung.de\/fileadmin\/redaktion\/DMP\/DMP1\/2025\u201311\u201310_Anhang_1_Patienten-Schulungsprogramme-DMP.pdf (last accessed on 26 November 2025)."},{"key":"10.3238\/arztebl.m2026.0009_ref14","doi-asserted-by":"crossref","unstructured":"Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al.: Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169","DOI":"10.1136\/bmj.d4169"},{"key":"10.3238\/arztebl.m2026.0009_ref15","doi-asserted-by":"crossref","unstructured":"Holman RR, Farmer AJ, Davies MJ, et al.: Three-year efficacy of complex insulin regimens in Type 2 diabetes: N Engl J Med 2009; 361: 1736\u201347","DOI":"10.1056\/NEJMoa0905479"},{"key":"10.3238\/arztebl.m2026.0009_ref16","doi-asserted-by":"crossref","unstructured":"M\u00fcller N, Lehmann T, Kl\u00f6ss A, G\u00fcnster C, Kloos C, M\u00fcller UA: Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: Analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication. Diabet Med 2020; 37: 1326\u201332","DOI":"10.1111\/dme.14294"},{"key":"10.3238\/arztebl.m2026.0009_ref17","unstructured":"Mertes B, Kuni\u00df N, Kramer G, Piorkowski M, Egidi G: NPH-Insulin zur Nacht ist 3- bis 12-mal preiswerter als etablierte Therapiestrategien bei der Ersteinstellung des Typ-2-Diabetes auf Insulin. 2021. 55. Kongress f\u00fcr Allgemeinmedizin und Familienmedizin. DOI: 10.3205\/21degam177."},{"key":"10.3238\/arztebl.m2026.0009_ref18","unstructured":"Barmer Institut f\u00fcr Gesundheitssystemforschung: Arzneimittelreport 2022 www.barmer.de\/resource\/blob\/1138136\/c95292f9376da884d3a5de65092c092f\/download-report-data.pdf (last accessed on 17 July 2025)."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:39:31Z","timestamp":1776767971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":18,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0009","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}